Home > Journals > Minerva Psichiatrica > Past Issues > Minerva Psichiatrica 2001 March;42(1) > Minerva Psichiatrica 2001 March;42(1):67-74

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

THERAPEUTICAL NOTES   

Minerva Psichiatrica 2001 March;42(1):67-74

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: Italian

Efficacy of long-acting venlafaxine in the treatment of dysthymia. An open-label trial

Rullo S., Parisi M.


PDF


Background. The clinical picture of dysthymia is often associated to a long-term decline of social functions. The aim of this paper is to evaluate the efficacy and safety of 150 mg/daily, long-acting venlafaxine, in the treatment of dysthimia in 20 outpatients, in an open-label study, for 3-months.
Methods. The efficacy was defined according to the changes of the HAMD, CGI, VGF (Wilcoxon test) scores. The safety was defined by the occurrence of side effects, during the period of treatment.
Results. The significant changes of HAMD, CGI, VGF began, respectively, at 30, 60 and 90 days. The use of venlafaxine was also related to a high safety.
Conclusions. The long-acting venlafaxine showed an efficacy and a high safety in the treatment of dysthymia.

top of page